Document is current
Any future updates will be listed below
-
Authors
Frykholm, Erik http://orcid.org/0000-0002-3212-4708
Klijn, Peter
Saey, Didier
van Hees, Hieronymus W. H.
Stål, Per
Sandström, Thomas
Sörlin, Ann
Maltais, François
Nyberg, André
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2016-01802)
The Swedish heart and lung association (E 127/16)
Hjärt-Lungfonden
Harald Jeanssons Foundation
Harald and Greta Jeanssons foundation
Erika and Rudolf Gustavsson fond
Insamlingsstiftelsen
- License Information
-
More Information
Article History
Received: 9 May 2018
Accepted: 11 December 2018
First Online: 3 January 2019
Ethics approval and consent to participate
: The study will be approved by the Regional Ethics Board at each included center. At the time for submission of this protocol, the study has been approved by the Regional Ethical Board in Umeå, Sweden (Dnr 2017-380-31 M). All participants will receive brief and comprehensible oral and written information, in accordance with the Helsinki Declaration [CitationRef removed]. Written information will be sent to all possible participants after a first contact by phone. Before commencing screening and outcome assessment, all procedures will be explained by the assessor and the informed consent form will be reviewed and signed.
: Not applicable.
: TS reports Advisory Board activities and lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK), Merck & Co, Novartis, and Teva. FM reports grants and lecture fees from Boehringer Ingelheim, GSK and Novartis. FM holds a CIHR/GSK Research Chair on COPD at Université Laval. AN reports lecture fees from AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
